|
Fusion Gene Summary | |
Fusion Gene ORF analysis | |
Fusion Genomic Features | |
Fusion Protein Features | |
Fusion Gene Sequence | |
Fusion Gene PPI analysis | |
Related Drugs | |
Related Diseases |
Fusion gene:CYP2C18-HELLS (FusionGDB2 ID:21040) |
Fusion Gene Summary for CYP2C18-HELLS |
Fusion gene summary |
Fusion gene information | Fusion gene name: CYP2C18-HELLS | Fusion gene ID: 21040 | Hgene | Tgene | Gene symbol | CYP2C18 | HELLS | Gene ID | 1562 | 3070 |
Gene name | cytochrome P450 family 2 subfamily C member 18 | helicase, lymphoid specific | |
Synonyms | CPCI|CYP2C|CYP2C17|P450-6B/29C|P450IIC17 | ICF4|LSH|Nbla10143|PASG|SMARCA6 | |
Cytomap | 10q23.33 | 10q23.33 | |
Type of gene | protein-coding | protein-coding | |
Description | cytochrome P450 2C18(S)-mephenytoin hydroxylase associated cytochrome P450CYPIIC18cytochrome P450, family 2, subfamily C, polypeptide 18cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 17cytochrome P450, subfamily IIC (mephenyt | lymphoid-specific helicaseSWI/SNF2-related, matrix-associated, actin-dependent regulator of chromatin, subfamily A, member 6proliferation-associated SNF2-like protein | |
Modification date | 20200313 | 20200322 | |
UniProtAcc | . | Q9NRZ9 | |
Ensembl transtripts involved in fusion gene | ENST00000339022, ENST00000285979, | ENST00000394036, ENST00000394045, ENST00000348459, ENST00000371332, ENST00000239026, ENST00000394044, ENST00000462057, | |
Fusion gene scores | * DoF score | 1 X 2 X 1=2 | 10 X 8 X 3=240 |
# samples | 2 | 11 | |
** MAII score | log2(2/2*10)=3.32192809488736 | log2(11/240*10)=-1.12553088208386 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: CYP2C18 [Title/Abstract] AND HELLS [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint | CYP2C18(96466717)-HELLS(96331145), # samples:5 | ||
Anticipated loss of major functional domain due to fusion event. | CYP2C18-HELLS seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. CYP2C18-HELLS seems lost the major protein functional domain in Tgene partner, which is a epigenetic factor due to the frame-shifted ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | CYP2C18 | GO:0042573 | retinoic acid metabolic process | 11093772 |
Fusion gene breakpoints across CYP2C18 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene breakpoints across HELLS (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerDB4 | LIHC | TCGA-BC-A8YO-01A | CYP2C18 | chr10 | 96493195 | + | HELLS | chr10 | 96331145 | + |
ChimerDB4 | LIHC | TCGA-ZS-A9CF-01A | CYP2C18 | chr10 | 96466717 | + | HELLS | chr10 | 96331145 | + |
ChimerDB4 | LIHC | TCGA-ZS-A9CF-01A | CYP2C18 | chr10 | 96466717 | + | HELLS | chr10 | 96331145 | + |
ChimerDB4 | LIHC | TCGA-ZS-A9CF-02A | CYP2C18 | chr10 | 96466717 | + | HELLS | chr10 | 96331145 | + |
ChimerDB4 | LIHC | TCGA-ZS-A9CF-01A | CYP2C18 | chr10 | 96466717 | - | HELLS | chr10 | 96331145 | + |
ChimerDB4 | LIHC | TCGA-ZS-A9CF-02A | CYP2C18 | chr10 | 96466717 | - | HELLS | chr10 | 96331145 | + |
Top |
Fusion Gene ORF analysis for CYP2C18-HELLS |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
Frame-shift | ENST00000339022 | ENST00000394036 | CYP2C18 | chr10 | 96493195 | + | HELLS | chr10 | 96331145 | + |
Frame-shift | ENST00000339022 | ENST00000394045 | CYP2C18 | chr10 | 96493195 | + | HELLS | chr10 | 96331145 | + |
Frame-shift | ENST00000339022 | ENST00000348459 | CYP2C18 | chr10 | 96493195 | + | HELLS | chr10 | 96331145 | + |
Frame-shift | ENST00000339022 | ENST00000371332 | CYP2C18 | chr10 | 96493195 | + | HELLS | chr10 | 96331145 | + |
5CDS-3UTR | ENST00000339022 | ENST00000239026 | CYP2C18 | chr10 | 96493195 | + | HELLS | chr10 | 96331145 | + |
5CDS-3UTR | ENST00000339022 | ENST00000394044 | CYP2C18 | chr10 | 96493195 | + | HELLS | chr10 | 96331145 | + |
5CDS-intron | ENST00000339022 | ENST00000462057 | CYP2C18 | chr10 | 96493195 | + | HELLS | chr10 | 96331145 | + |
Frame-shift | ENST00000285979 | ENST00000394036 | CYP2C18 | chr10 | 96493195 | + | HELLS | chr10 | 96331145 | + |
Frame-shift | ENST00000285979 | ENST00000394045 | CYP2C18 | chr10 | 96493195 | + | HELLS | chr10 | 96331145 | + |
Frame-shift | ENST00000285979 | ENST00000348459 | CYP2C18 | chr10 | 96493195 | + | HELLS | chr10 | 96331145 | + |
Frame-shift | ENST00000285979 | ENST00000371332 | CYP2C18 | chr10 | 96493195 | + | HELLS | chr10 | 96331145 | + |
5CDS-3UTR | ENST00000285979 | ENST00000239026 | CYP2C18 | chr10 | 96493195 | + | HELLS | chr10 | 96331145 | + |
5CDS-3UTR | ENST00000285979 | ENST00000394044 | CYP2C18 | chr10 | 96493195 | + | HELLS | chr10 | 96331145 | + |
5CDS-intron | ENST00000285979 | ENST00000462057 | CYP2C18 | chr10 | 96493195 | + | HELLS | chr10 | 96331145 | + |
intron-3CDS | ENST00000339022 | ENST00000394036 | CYP2C18 | chr10 | 96466717 | + | HELLS | chr10 | 96331145 | + |
intron-3CDS | ENST00000339022 | ENST00000394045 | CYP2C18 | chr10 | 96466717 | + | HELLS | chr10 | 96331145 | + |
intron-3CDS | ENST00000339022 | ENST00000348459 | CYP2C18 | chr10 | 96466717 | + | HELLS | chr10 | 96331145 | + |
intron-3CDS | ENST00000339022 | ENST00000371332 | CYP2C18 | chr10 | 96466717 | + | HELLS | chr10 | 96331145 | + |
intron-3UTR | ENST00000339022 | ENST00000239026 | CYP2C18 | chr10 | 96466717 | + | HELLS | chr10 | 96331145 | + |
intron-3UTR | ENST00000339022 | ENST00000394044 | CYP2C18 | chr10 | 96466717 | + | HELLS | chr10 | 96331145 | + |
intron-intron | ENST00000339022 | ENST00000462057 | CYP2C18 | chr10 | 96466717 | + | HELLS | chr10 | 96331145 | + |
Frame-shift | ENST00000285979 | ENST00000394036 | CYP2C18 | chr10 | 96466717 | + | HELLS | chr10 | 96331145 | + |
In-frame | ENST00000285979 | ENST00000394045 | CYP2C18 | chr10 | 96466717 | + | HELLS | chr10 | 96331145 | + |
In-frame | ENST00000285979 | ENST00000348459 | CYP2C18 | chr10 | 96466717 | + | HELLS | chr10 | 96331145 | + |
In-frame | ENST00000285979 | ENST00000371332 | CYP2C18 | chr10 | 96466717 | + | HELLS | chr10 | 96331145 | + |
5CDS-3UTR | ENST00000285979 | ENST00000239026 | CYP2C18 | chr10 | 96466717 | + | HELLS | chr10 | 96331145 | + |
5CDS-3UTR | ENST00000285979 | ENST00000394044 | CYP2C18 | chr10 | 96466717 | + | HELLS | chr10 | 96331145 | + |
5CDS-intron | ENST00000285979 | ENST00000462057 | CYP2C18 | chr10 | 96466717 | + | HELLS | chr10 | 96331145 | + |
ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000285979 | CYP2C18 | chr10 | 96466717 | + | ENST00000394045 | HELLS | chr10 | 96331145 | + | 3282 | 1018 | 199 | 2805 | 868 |
ENST00000285979 | CYP2C18 | chr10 | 96466717 | + | ENST00000348459 | HELLS | chr10 | 96331145 | + | 3577 | 1018 | 199 | 3099 | 966 |
ENST00000285979 | CYP2C18 | chr10 | 96466717 | + | ENST00000371332 | HELLS | chr10 | 96331145 | + | 3238 | 1018 | 199 | 3237 | 1013 |
DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
ENST00000285979 | ENST00000394045 | CYP2C18 | chr10 | 96466717 | + | HELLS | chr10 | 96331145 | + | 0.000191914 | 0.99980813 |
ENST00000285979 | ENST00000348459 | CYP2C18 | chr10 | 96466717 | + | HELLS | chr10 | 96331145 | + | 0.000110872 | 0.99988914 |
ENST00000285979 | ENST00000371332 | CYP2C18 | chr10 | 96466717 | + | HELLS | chr10 | 96331145 | + | 0.000158149 | 0.9998418 |
Top |
Fusion Genomic Features for CYP2C18-HELLS |
FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
CYP2C18 | chr10 | 96493195 | + | HELLS | chr10 | 96331144 | + | 5.65E-05 | 0.9999435 |
CYP2C18 | chr10 | 96466717 | + | HELLS | chr10 | 96331144 | + | 1.88E-08 | 1 |
CYP2C18 | chr10 | 96466717 | + | HELLS | chr10 | 96331144 | + | 1.88E-08 | 1 |
CYP2C18 | chr10 | 96493195 | + | HELLS | chr10 | 96331144 | + | 5.65E-05 | 0.9999435 |
CYP2C18 | chr10 | 96466717 | + | HELLS | chr10 | 96331144 | + | 1.88E-08 | 1 |
CYP2C18 | chr10 | 96466717 | + | HELLS | chr10 | 96331144 | + | 1.88E-08 | 1 |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for CYP2C18-HELLS |
Go to FGviewer for the breakpoints of chr10:96466717-chr10:96331145 - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
. | HELLS |
FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. | FUNCTION: Plays an essential role in normal development and survival. Involved in regulation of the expansion or survival of lymphoid cells. Required for de novo or maintenance DNA methylation. May control silencing of the imprinted CDKN1C gene through DNA methylation. May play a role in formation and organization of heterochromatin, implying a functional role in the regulation of transcription and mitosis (By similarity). {ECO:0000250|UniProtKB:Q60848}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Tgene | HELLS | chr10:96466717 | chr10:96331145 | ENST00000348459 | 5 | 22 | 235_403 | 145.0 | 839.0 | Domain | Helicase ATP-binding | |
Tgene | HELLS | chr10:96466717 | chr10:96331145 | ENST00000348459 | 5 | 22 | 603_767 | 145.0 | 839.0 | Domain | Helicase C-terminal | |
Tgene | HELLS | chr10:96466717 | chr10:96331145 | ENST00000394036 | 4 | 21 | 235_403 | 123.33333333333333 | 338.3333333333333 | Domain | Helicase ATP-binding | |
Tgene | HELLS | chr10:96466717 | chr10:96331145 | ENST00000394036 | 4 | 21 | 603_767 | 123.33333333333333 | 338.3333333333333 | Domain | Helicase C-terminal | |
Tgene | HELLS | chr10:96466717 | chr10:96331145 | ENST00000394044 | 5 | 11 | 235_403 | 145.0 | 316.0 | Domain | Helicase ATP-binding | |
Tgene | HELLS | chr10:96466717 | chr10:96331145 | ENST00000394044 | 5 | 11 | 603_767 | 145.0 | 316.0 | Domain | Helicase C-terminal | |
Tgene | HELLS | chr10:96466717 | chr10:96331145 | ENST00000394045 | 5 | 20 | 235_403 | 145.0 | 741.0 | Domain | Helicase ATP-binding | |
Tgene | HELLS | chr10:96466717 | chr10:96331145 | ENST00000394045 | 5 | 20 | 603_767 | 145.0 | 741.0 | Domain | Helicase C-terminal | |
Tgene | HELLS | chr10:96466717 | chr10:96331145 | ENST00000348459 | 5 | 22 | 354_357 | 145.0 | 839.0 | Motif | DEAH box | |
Tgene | HELLS | chr10:96466717 | chr10:96331145 | ENST00000394036 | 4 | 21 | 354_357 | 123.33333333333333 | 338.3333333333333 | Motif | DEAH box | |
Tgene | HELLS | chr10:96466717 | chr10:96331145 | ENST00000394044 | 5 | 11 | 354_357 | 145.0 | 316.0 | Motif | DEAH box | |
Tgene | HELLS | chr10:96466717 | chr10:96331145 | ENST00000394045 | 5 | 20 | 354_357 | 145.0 | 741.0 | Motif | DEAH box | |
Tgene | HELLS | chr10:96466717 | chr10:96331145 | ENST00000348459 | 5 | 22 | 248_255 | 145.0 | 839.0 | Nucleotide binding | ATP | |
Tgene | HELLS | chr10:96466717 | chr10:96331145 | ENST00000394036 | 4 | 21 | 248_255 | 123.33333333333333 | 338.3333333333333 | Nucleotide binding | ATP | |
Tgene | HELLS | chr10:96466717 | chr10:96331145 | ENST00000394044 | 5 | 11 | 248_255 | 145.0 | 316.0 | Nucleotide binding | ATP | |
Tgene | HELLS | chr10:96466717 | chr10:96331145 | ENST00000394045 | 5 | 20 | 248_255 | 145.0 | 741.0 | Nucleotide binding | ATP |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Tgene | HELLS | chr10:96466717 | chr10:96331145 | ENST00000348459 | 5 | 22 | 30_115 | 145.0 | 839.0 | Coiled coil | Ontology_term=ECO:0000255 | |
Tgene | HELLS | chr10:96466717 | chr10:96331145 | ENST00000394036 | 4 | 21 | 30_115 | 123.33333333333333 | 338.3333333333333 | Coiled coil | Ontology_term=ECO:0000255 | |
Tgene | HELLS | chr10:96466717 | chr10:96331145 | ENST00000394044 | 5 | 11 | 30_115 | 145.0 | 316.0 | Coiled coil | Ontology_term=ECO:0000255 | |
Tgene | HELLS | chr10:96466717 | chr10:96331145 | ENST00000394045 | 5 | 20 | 30_115 | 145.0 | 741.0 | Coiled coil | Ontology_term=ECO:0000255 |
Top |
Fusion Gene Sequence for CYP2C18-HELLS |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
>In-frame_ENST00000285979_ENST00000394045_TCGA-ZS-A9CF-01A_CYP2C18_chr10_96466717_+_HELLS_chr10_96331145_length(transcript)=3282nt_BP=1018nt GGCACCGGAAAGAACAAGAAAAAAGAACACCTTATTTTTATCTTCTTCAGTGAGCCAATGTTCATTCAAAAGAGAGATTAAAGTGCTTTT TGCTGACTAGTCACAGTCAGAGTCAGAATCACAGGTGGATTAGTAGGGAGTGTTATAAAAGCCTTGAAGTGAAAGCCCGCAGTTGTCTTA CTAAGAAGAGAAGCCTTCAATGGATCCAGCTGTGGCTCTGGTGCTCTGTCTCTCCTGTTTGTTTCTCCTTTCACTCTGGAGGCAGAGCTC TGGAAGAGGGAGGCTCCCGTCTGGCCCCACTCCTCTCCCGATTATTGGAAATATCCTGCAGTTAGATGTTAAGGACATGAGCAAATCCTT AACCAATTTCTCAAAAGTCTATGGCCCTGTGTTCACTGTGTATTTTGGCCTGAAGCCCATTGTGGTGTTGCATGGATATGAAGCAGTGAA GGAGGCCCTGATTGATCATGGAGAGGAGTTTTCTGGAAGAGGAAGTTTTCCAGTGGCTGAAAAAGTTAACAAAGGACTTGGAATCCTTTT CAGCAATGGAAAGAGATGGAAGGAGATCCGGCGTTTCTGCCTCATGACTCTGCGGAATTTTGGGATGGGGAAGAGGAGCATCGAGGACCG TGTTCAAGAGGAAGCCCGCTGCCTTGTGGAGGAGTTGAGAAAAACCAATGCCTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCC CTGCAATGTGATCTGCTCTGTTATTTTCCATGATCGATTTGATTATAAAGATCAGAGGTTTCTTAACTTGATGGAAAAATTCAATGAAAA CCTCAGGATTCTGAGCTCTCCATGGATCCAGGTCTGCAATAATTTCCCTGCTCTCATCGATTATCTCCCAGGAAGTCATAATAAAATAGC TGAAAATTTTGCTTACATTAAAAGTTATGTATTGGAGAGAATAAAAGAACATCAAGAATCCCTGGACATGAACAGTGCTCGGGACTTTAT TGATTGTTTCCTGATCAAAATGGAACAGGAAATTTTGTCTGTGGCTAAAAAAAATAAAAAGGAGAATGAGGATGAAAACTCCTCCTCTAC TAATCTCTGTGTGGAAGATCTTCAGAAAAATAAAGATTCGAATAGTATAATTAAAGATAGATTGTCTGAAACGGTTAGGCAGAATACTAA ATTCTTTTTTGACCCAGTCCGGAAGTGTAATGGTCAGCCAGTACCTTTTCAACAACCAAAGCACTTCACTGGAGGAGTGATGCGATGGTA CCAAGTAGAAGGCATGGAATGGCTTAGGATGCTTTGGGAAAATGGAATTAATGGCATTTTAGCAGATGAAATGGGATTGGGTAAGACAGT TCAGTGCATTGCTACTATTGCATTGATGATTCAGAGAGGAGTACCAGGACCTTTTCTTGTCTGTGGCCCTTTGTCTACACTTCCTAACTG GATGGCTGAATTCAAAAGATTTACACCAGATATCCCTACAATGTTATATCATGGAACCCAGGAGGAACGTCAAAAATTGGTAAGAAATAT TTACAAACGGAAAGGGACTTTGCAGATTCATCCTGTGGTAATCACGTCATTTGAAATAGCCATGAGAGACCGAAATGCGTTACAGATTTT AACACCTTTCTTATTGAGAAGACTGAAGTCTGATGTTGCTCTTGAAGTTCCTCCTAAACGAGAAGTAGTCGTTTATGCTCCACTTTCAAA GAAGCAGGAGATCTTTTATACAGCCATTGTGAACCGTACAATTGCAAACATGTTTGGATCCAGTGAGAAAGAAACAATTGAGTTAAGTCC TACTGGTCGACCAAAACGACGAACTAGAAAATCAATAAATTACAGCAAAATAGATGATTTCCCTAATGAATTGGAAAAACTGATCAGTCA AATACAGCCAGAGGTGGACCGAGAAAGAGCTGTTGTGGAAGTGAATATCCCTGTAGAATCTGAAGTTAATCTGAAGCTGCAGAATATAAT GATGCTACTTCGTAAATGTTGTAATCATCCATATTTGATTGAATATCCTATAGACCCTGTTACACAAGAATTTAAGATCGATGAAGAATT GGTAACAAATTCTGGGAAGTTCTTGATTTTGGATCGAATGCTGCCAGAACTAAAAAAAAGAGGTCACAAGGTGCTGCTTTTTTCACAAAT GACAAGCATGTTGGACATTTTGATGGATTACTGCCATCTCAGAGATTTCAACTTCAGCAGGCTTGATGGGTCCATGTCTTACTCAGAGAG AGAAAAAAACATGCACAGCTTCAACACGGATCCAGAGGTGTTTATCTTCTTAGTGAGTACACGAGCTGGTGGCCTGGGCATTAATCTGAC TGCAGCAGATACAGTTATCATTTATGATAGTGATTGGAACCCCCAGTCGGATCTTCAGGCCCAGGATAGATGTCATAGAATTGGTCAGAC AAAGCCAGTTGTTGTTTATCGCCTTGTTACAGCAAATACTATCGATCAGAAAATTGTGGAAAGAGCAGCTGCTAAAAGGAAACTGGAAAA GTTGATCATCCATAAAAATCATTTCAAAGGTGGTCAGTCTGGATTAAATCTGTCTAAGAATTTCTTAGATCCTAAGGAATTAATGGAATT ATTAAAATCTAGAGATTATGAAAGGGAAATAAAAGGATCAAGAGAGAAGGTCATTAGTGATAAAGATCTAGAGTTGTTGTTAGATCGAAG TGATCTTATTGATCAAATGAATGCTTCAGGACCAATTAAAGAGAAGATGGGGATATTCAAGATATTAGAAAATTCTGAAGATTCCAGTCC TGAATGTTTGTTTTAAAGTGGAGCTCAAGAATAGCTTTTAAAAGTTCTTATTTACATCTAGTGATTTCCCTGTATTGGGTTTGAAATACT GATTGTCCACTTCACCTTTTTTATTATATCAGTTGACATGTAACTAGTACCATGCGTACTTAAATAGATGGTAATTTTCTGAGCCTTACC AAGAACAAAGAAGTATCCATATTAAGTTTAGATTTTCAGTTAATTTTTGAGACTGAGTAGTATTCTTGGATACAGGCTGATGTGTACTTA ACCACTTCCAGATTTATACAGTCTTCCTGTGGAAGTTTAGTAAATGTCTTTTTCCCTCCTTTCTTCTAGTAATGCAGTTCATGGGCTTTA GGTACTTCAGTTATGAAGTAGGCTTTTCATGGGGAGAGATTGGGATTATGCTCTCTGTTGTTTAAGAAACTGTTTGATTTTAGAGTCTAT >In-frame_ENST00000285979_ENST00000394045_TCGA-ZS-A9CF-01A_CYP2C18_chr10_96466717_+_HELLS_chr10_96331145_length(amino acids)=868AA_start in transcript=199_stop in transcript=2805 MDPAVALVLCLSCLFLLSLWRQSSGRGRLPSGPTPLPIIGNILQLDVKDMSKSLTNFSKVYGPVFTVYFGLKPIVVLHGYEAVKEALIDH GEEFSGRGSFPVAEKVNKGLGILFSNGKRWKEIRRFCLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTNASPCDPTFILGCAPCNVICS VIFHDRFDYKDQRFLNLMEKFNENLRILSSPWIQVCNNFPALIDYLPGSHNKIAENFAYIKSYVLERIKEHQESLDMNSARDFIDCFLIK MEQEILSVAKKNKKENEDENSSSTNLCVEDLQKNKDSNSIIKDRLSETVRQNTKFFFDPVRKCNGQPVPFQQPKHFTGGVMRWYQVEGME WLRMLWENGINGILADEMGLGKTVQCIATIALMIQRGVPGPFLVCGPLSTLPNWMAEFKRFTPDIPTMLYHGTQEERQKLVRNIYKRKGT LQIHPVVITSFEIAMRDRNALQILTPFLLRRLKSDVALEVPPKREVVVYAPLSKKQEIFYTAIVNRTIANMFGSSEKETIELSPTGRPKR RTRKSINYSKIDDFPNELEKLISQIQPEVDRERAVVEVNIPVESEVNLKLQNIMMLLRKCCNHPYLIEYPIDPVTQEFKIDEELVTNSGK FLILDRMLPELKKRGHKVLLFSQMTSMLDILMDYCHLRDFNFSRLDGSMSYSEREKNMHSFNTDPEVFIFLVSTRAGGLGINLTAADTVI IYDSDWNPQSDLQAQDRCHRIGQTKPVVVYRLVTANTIDQKIVERAAAKRKLEKLIIHKNHFKGGQSGLNLSKNFLDPKELMELLKSRDY -------------------------------------------------------------- >In-frame_ENST00000285979_ENST00000348459_TCGA-ZS-A9CF-01A_CYP2C18_chr10_96466717_+_HELLS_chr10_96331145_length(transcript)=3577nt_BP=1018nt GGCACCGGAAAGAACAAGAAAAAAGAACACCTTATTTTTATCTTCTTCAGTGAGCCAATGTTCATTCAAAAGAGAGATTAAAGTGCTTTT TGCTGACTAGTCACAGTCAGAGTCAGAATCACAGGTGGATTAGTAGGGAGTGTTATAAAAGCCTTGAAGTGAAAGCCCGCAGTTGTCTTA CTAAGAAGAGAAGCCTTCAATGGATCCAGCTGTGGCTCTGGTGCTCTGTCTCTCCTGTTTGTTTCTCCTTTCACTCTGGAGGCAGAGCTC TGGAAGAGGGAGGCTCCCGTCTGGCCCCACTCCTCTCCCGATTATTGGAAATATCCTGCAGTTAGATGTTAAGGACATGAGCAAATCCTT AACCAATTTCTCAAAAGTCTATGGCCCTGTGTTCACTGTGTATTTTGGCCTGAAGCCCATTGTGGTGTTGCATGGATATGAAGCAGTGAA GGAGGCCCTGATTGATCATGGAGAGGAGTTTTCTGGAAGAGGAAGTTTTCCAGTGGCTGAAAAAGTTAACAAAGGACTTGGAATCCTTTT CAGCAATGGAAAGAGATGGAAGGAGATCCGGCGTTTCTGCCTCATGACTCTGCGGAATTTTGGGATGGGGAAGAGGAGCATCGAGGACCG TGTTCAAGAGGAAGCCCGCTGCCTTGTGGAGGAGTTGAGAAAAACCAATGCCTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCC CTGCAATGTGATCTGCTCTGTTATTTTCCATGATCGATTTGATTATAAAGATCAGAGGTTTCTTAACTTGATGGAAAAATTCAATGAAAA CCTCAGGATTCTGAGCTCTCCATGGATCCAGGTCTGCAATAATTTCCCTGCTCTCATCGATTATCTCCCAGGAAGTCATAATAAAATAGC TGAAAATTTTGCTTACATTAAAAGTTATGTATTGGAGAGAATAAAAGAACATCAAGAATCCCTGGACATGAACAGTGCTCGGGACTTTAT TGATTGTTTCCTGATCAAAATGGAACAGGAAATTTTGTCTGTGGCTAAAAAAAATAAAAAGGAGAATGAGGATGAAAACTCCTCCTCTAC TAATCTCTGTGTGGAAGATCTTCAGAAAAATAAAGATTCGAATAGTATAATTAAAGATAGATTGTCTGAAACGGTTAGGCAGAATACTAA ATTCTTTTTTGACCCAGTCCGGAAGTGTAATGGTCAGCCAGTACCTTTTCAACAACCAAAGCACTTCACTGGAGGAGTGATGCGATGGTA CCAAGTAGAAGGCATGGAATGGCTTAGGATGCTTTGGGAAAATGGAATTAATGGCATTTTAGCAGATGAAATGGGATTGGGTAAGACAGT TCAGTGCATTGCTACTATTGCATTGATGATTCAGAGAGGAGTACCAGGACCTTTTCTTGTCTGTGGCCCTTTGTCTACACTTCCTAACTG GATGGCTGAATTCAAAAGATTTACACCAGATATCCCTACAATGTTATATCATGGAACCCAGGAGGAACGTCAAAAATTGGTAAGAAATAT TTACAAACGGAAAGGGACTTTGCAGATTCATCCTGTGGTAATCACGTCATTTGAAATAGCCATGAGAGACCGAAATGCGTTACAGCATTG CTATTGGAAATACTTAATAGTAGATGAAGGACACAGGATTAAGAATATGAAGTGCCGTCTAATCAGGGAGTTAAAACGATTCAATGCTGA TAACAAACTTCTTTTGACTGGTACTCCCTTGCAAAACAATTTATCAGAACTTTGGTCATTGCTAAACTTTTTGTTGCCAGATGTATTTGA TGACTTGAAAAGCTTTGAGTCTTGGTTTGACATCACTAGTCTTTCTGAAACTGCTGAAGATATTATTGCTAAAGAAAGAGAACAGAATGT ATTGCATATGCTGCACCAGATTTTAACACCTTTCTTATTGAGAAGACTGAAGTCTGATGTTGCTCTTGAAGTTCCTCCTAAACGAGAAGT AGTCGTTTATGCTCCACTTTCAAAGAAGCAGGAGATCTTTTATACAGCCATTGTGAACCGTACAATTGCAAACATGTTTGGATCCAGTGA GAAAGAAACAATTGAGTTAAGTCCTACTGGTCGACCAAAACGACGAACTAGAAAATCAATAAATTACAGCAAAATAGATGATTTCCCTAA TGAATTGGAAAAACTGATCAGTCAAATACAGCCAGAGGTGGACCGAGAAAGAGCTGTTGTGGAAGTGAATATCCCTGTAGAATCTGAAGT TAATCTGAAGCTGCAGAATATAATGATGCTACTTCGTAAATGTTGTAATCATCCATATTTGATTGAATATCCTATAGACCCTGTTACACA AGAATTTAAGATCGATGAAGAATTGGTAACAAATTCTGGGAAGTTCTTGATTTTGGATCGAATGCTGCCAGAACTAAAAAAAAGAGGTCA CAAGGTGCTGCTTTTTTCACAAATGACAAGCATGTTGGACATTTTGATGGATTACTGCCATCTCAGAGATTTCAACTTCAGCAGGCTTGA TGGGTCCATGTCTTACTCAGAGAGAGAAAAAAACATGCACAGCTTCAACACGGATCCAGAGGTGTTTATCTTCTTAGTGAGTACACGAGC TGGTGGCCTGGGCATTAATCTGACTGCAGCAGATACAGTTATCATTTATGATAGTGATTGGAACCCCCAGTCGGATCTTCAGGCCCAGGA TAGATGTCATAGAATTGGTCAGACAAAGCCAGTTGTTGTTTATCGCCTTGTTACAGCAAATACTATCGATCAGAAAATTGTGGAAAGAGC AGCTGCTAAAAGGAAACTGGAAAAGTTGATCATCCATAAAAATCATTTCAAAGGTGGTCAGTCTGGATTAAATCTGTCTAAGAATTTCTT AGATCCTAAGGAATTAATGGAATTATTAAAATCTAGAGATTATGAAAGGGAAATAAAAGGATCAAGAGAGAAGGTCATTAGTGATAAAGA TCTAGAGTTGTTGTTAGATCGAAGTGATCTTATTGATCAAATGAATGCTTCAGGACCAATTAAAGAGAAGATGGGGATATTCAAGATATT AGAAAATTCTGAAGATTCCAGTCCTGAATGTTTGTTTTAAAGTGGAGCTCAAGAATAGCTTTTAAAAGTTCTTATTTACATCTAGTGATT TCCCTGTATTGGGTTTGAAATACTGATTGTCCACTTCACCTTTTTTATTATATCAGTTGACATGTAACTAGTACCATGCGTACTTAAATA GATGGTAATTTTCTGAGCCTTACCAAGAACAAAGAAGTATCCATATTAAGTTTAGATTTTCAGTTAATTTTTGAGACTGAGTAGTATTCT TGGATACAGGCTGATGTGTACTTAACCACTTCCAGATTTATACAGTCTTCCTGTGGAAGTTTAGTAAATGTCTTTTTCCCTCCTTTCTTC TAGTAATGCAGTTCATGGGCTTTAGGTACTTCAGTTATGAAGTAGGCTTTTCATGGGGAGAGATTGGGATTATGCTCTCTGTTGTTTAAG >In-frame_ENST00000285979_ENST00000348459_TCGA-ZS-A9CF-01A_CYP2C18_chr10_96466717_+_HELLS_chr10_96331145_length(amino acids)=966AA_start in transcript=199_stop in transcript=3099 MDPAVALVLCLSCLFLLSLWRQSSGRGRLPSGPTPLPIIGNILQLDVKDMSKSLTNFSKVYGPVFTVYFGLKPIVVLHGYEAVKEALIDH GEEFSGRGSFPVAEKVNKGLGILFSNGKRWKEIRRFCLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTNASPCDPTFILGCAPCNVICS VIFHDRFDYKDQRFLNLMEKFNENLRILSSPWIQVCNNFPALIDYLPGSHNKIAENFAYIKSYVLERIKEHQESLDMNSARDFIDCFLIK MEQEILSVAKKNKKENEDENSSSTNLCVEDLQKNKDSNSIIKDRLSETVRQNTKFFFDPVRKCNGQPVPFQQPKHFTGGVMRWYQVEGME WLRMLWENGINGILADEMGLGKTVQCIATIALMIQRGVPGPFLVCGPLSTLPNWMAEFKRFTPDIPTMLYHGTQEERQKLVRNIYKRKGT LQIHPVVITSFEIAMRDRNALQHCYWKYLIVDEGHRIKNMKCRLIRELKRFNADNKLLLTGTPLQNNLSELWSLLNFLLPDVFDDLKSFE SWFDITSLSETAEDIIAKEREQNVLHMLHQILTPFLLRRLKSDVALEVPPKREVVVYAPLSKKQEIFYTAIVNRTIANMFGSSEKETIEL SPTGRPKRRTRKSINYSKIDDFPNELEKLISQIQPEVDRERAVVEVNIPVESEVNLKLQNIMMLLRKCCNHPYLIEYPIDPVTQEFKIDE ELVTNSGKFLILDRMLPELKKRGHKVLLFSQMTSMLDILMDYCHLRDFNFSRLDGSMSYSEREKNMHSFNTDPEVFIFLVSTRAGGLGIN LTAADTVIIYDSDWNPQSDLQAQDRCHRIGQTKPVVVYRLVTANTIDQKIVERAAAKRKLEKLIIHKNHFKGGQSGLNLSKNFLDPKELM -------------------------------------------------------------- >In-frame_ENST00000285979_ENST00000371332_TCGA-ZS-A9CF-01A_CYP2C18_chr10_96466717_+_HELLS_chr10_96331145_length(transcript)=3238nt_BP=1018nt GGCACCGGAAAGAACAAGAAAAAAGAACACCTTATTTTTATCTTCTTCAGTGAGCCAATGTTCATTCAAAAGAGAGATTAAAGTGCTTTT TGCTGACTAGTCACAGTCAGAGTCAGAATCACAGGTGGATTAGTAGGGAGTGTTATAAAAGCCTTGAAGTGAAAGCCCGCAGTTGTCTTA CTAAGAAGAGAAGCCTTCAATGGATCCAGCTGTGGCTCTGGTGCTCTGTCTCTCCTGTTTGTTTCTCCTTTCACTCTGGAGGCAGAGCTC TGGAAGAGGGAGGCTCCCGTCTGGCCCCACTCCTCTCCCGATTATTGGAAATATCCTGCAGTTAGATGTTAAGGACATGAGCAAATCCTT AACCAATTTCTCAAAAGTCTATGGCCCTGTGTTCACTGTGTATTTTGGCCTGAAGCCCATTGTGGTGTTGCATGGATATGAAGCAGTGAA GGAGGCCCTGATTGATCATGGAGAGGAGTTTTCTGGAAGAGGAAGTTTTCCAGTGGCTGAAAAAGTTAACAAAGGACTTGGAATCCTTTT CAGCAATGGAAAGAGATGGAAGGAGATCCGGCGTTTCTGCCTCATGACTCTGCGGAATTTTGGGATGGGGAAGAGGAGCATCGAGGACCG TGTTCAAGAGGAAGCCCGCTGCCTTGTGGAGGAGTTGAGAAAAACCAATGCCTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCC CTGCAATGTGATCTGCTCTGTTATTTTCCATGATCGATTTGATTATAAAGATCAGAGGTTTCTTAACTTGATGGAAAAATTCAATGAAAA CCTCAGGATTCTGAGCTCTCCATGGATCCAGGTCTGCAATAATTTCCCTGCTCTCATCGATTATCTCCCAGGAAGTCATAATAAAATAGC TGAAAATTTTGCTTACATTAAAAGTTATGTATTGGAGAGAATAAAAGAACATCAAGAATCCCTGGACATGAACAGTGCTCGGGACTTTAT TGATTGTTTCCTGATCAAAATGGAACAGGAAATTTTGTCTGTGGCTAAAAAAAATAAAAAGGAGAATGAGGATGAAAACTCCTCCTCTAC TAATCTCTGTGTGGAAGATCTTCAGAAAAATAAAGATTCGAATAGTATAATTAAAGATAGATTGTCTGAAACGGTTAGGCAGAATACTAA ATTCTTTTTTGACCCAGTCCGGAAGTGTAATGGTCAGCCAGTACCTTTTCAACAACCAAAGCACTTCACTGGAGGAGTGATGCGATGGTA CCAAGTAGAAGGCATGGAATGGCTTAGGATGCTTTGGGAAAATGGAATTAATGGCATTTTAGCAGATGAAATGGGATTGGGTAAGACAGT TCAGTGCATTGCTACTATTGCATTGATGATTCAGAGAGGAGTACCAGGACCTTTTCTTGTCTGTGGCCCTTTGTCTACACTTCCTAACTG GATGGCTGAATTCAAAAGATTTACACCAGATATCCCTACAATGTTATATCATGGAACCCAGGAGGAACGTCAAAAATTGGTAAGAAATAT TTACAAACGGAAAGGGACTTTGCAGATTCATCCTGTGGTAATCACGTCATTTGAAATAGCCATGAGAGACCGAAATGCGTTACAGCATTG CTATTGGAAATACTTAATAGTAGATGAAGGACACAGGATTAAGAATATGAAGTGCCGTCTAATCAGGGAGTTAAAACGATTCAATGCTGA TAACAAACTTCTTTTGACTGGTACTCCCTTGCAAAACAATTTATCAGAACTTTGGTCATTGCTAAACTTTTTGTTGCCAGATGTATTTGA TGACTTGAAAAGCTTTGAGTCTTGGTTTGACATCACTAGTCTTTCTGAAACTGCTGAAGATATTATTGCTAAAGAAAGAGAACAGAATGT ATTGCATATGCTGCACCAGGAAAGAATTCCTAGAATGTATGTGTCAGAGTTTACAGATGAGGGCTTCTTTGAAGGCAAATTGCCCTCCAG AAAAGATTTATATGATATACGTCCATATGAAAATACTTATTTACTCAAGCTTCATACCAATTTTGAGATTTTAACACCTTTCTTATTGAG AAGACTGAAGTCTGATGTTGCTCTTGAAGTTCCTCCTAAACGAGAAGTAGTCGTTTATGCTCCACTTTCAAAGAAGCAGGAGATCTTTTA TACAGCCATTGTGAACCGTACAATTGCAAACATGTTTGGATCCAGTGAGAAAGAAACAATTGAGTTAAGTCCTACTGGTCGACCAAAACG ACGAACTAGAAAATCAATAAATTACAGCAAAATAGATGATTTCCCTAATGAATTGGAAAAACTGATCAGTCAAATACAGCCAGAGGTGGA CCGAGAAAGAGCTGTTGTGGAAGTGAATATCCCTGTAGAATCTGAAGTTAATCTGAAGCTGCAGAATATAATGATGCTACTTCGTAAATG TTGTAATCATCCATATTTGATTGAATATCCTATAGACCCTGTTACACAAGAATTTAAGATCGATGAAGAATTGGTAACAAATTCTGGGAA GTTCTTGATTTTGGATCGAATGCTGCCAGAACTAAAAAAAAGAGGTCACAAGGTGCTGCTTTTTTCACAAATGACAAGCATGTTGGACAT TTTGATGGATTACTGCCATCTCAGAGATTTCAACTTCAGCAGGCTTGATGGGTCCATGTCTTACTCAGAGAGAGAAAAAAACATGCACAG CTTCAACACGGATCCAGAGGTGTTTATCTTCTTAGTGAGTACACGAGCTGGTGGCCTGGGCATTAATCTGACTGCAGCAGATACAGTTAT CATTTATGATAGTGATTGGAACCCCCAGTCGGATCTTCAGGCCCAGGATAGATGTCATAGAATTGGTCAGACAAAGCCAGTTGTTGTTTA TCGCCTTGTTACAGCAAATACTATCGATCAGAAAATTGTGGAAAGAGCAGCTGCTAAAAGGAAACTGGAAAAGTTGATCATCCATAAAAA TCATTTCAAAGGTGGTCAGTCTGGATTAAATCTGTCTAAGAATTTCTTAGATCCTAAGGAATTAATGGAATTATTAAAATCTAGAGATTA TGAAAGGGAAATAAAAGGATCAAGAGAGAAGGTCATTAGTGATAAAGATCTAGAGTTGTTGTTAGATCGAAGTGATCTTATTGATCAAAT >In-frame_ENST00000285979_ENST00000371332_TCGA-ZS-A9CF-01A_CYP2C18_chr10_96466717_+_HELLS_chr10_96331145_length(amino acids)=1013AA_start in transcript=199_stop in transcript=3237 MDPAVALVLCLSCLFLLSLWRQSSGRGRLPSGPTPLPIIGNILQLDVKDMSKSLTNFSKVYGPVFTVYFGLKPIVVLHGYEAVKEALIDH GEEFSGRGSFPVAEKVNKGLGILFSNGKRWKEIRRFCLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTNASPCDPTFILGCAPCNVICS VIFHDRFDYKDQRFLNLMEKFNENLRILSSPWIQVCNNFPALIDYLPGSHNKIAENFAYIKSYVLERIKEHQESLDMNSARDFIDCFLIK MEQEILSVAKKNKKENEDENSSSTNLCVEDLQKNKDSNSIIKDRLSETVRQNTKFFFDPVRKCNGQPVPFQQPKHFTGGVMRWYQVEGME WLRMLWENGINGILADEMGLGKTVQCIATIALMIQRGVPGPFLVCGPLSTLPNWMAEFKRFTPDIPTMLYHGTQEERQKLVRNIYKRKGT LQIHPVVITSFEIAMRDRNALQHCYWKYLIVDEGHRIKNMKCRLIRELKRFNADNKLLLTGTPLQNNLSELWSLLNFLLPDVFDDLKSFE SWFDITSLSETAEDIIAKEREQNVLHMLHQERIPRMYVSEFTDEGFFEGKLPSRKDLYDIRPYENTYLLKLHTNFEILTPFLLRRLKSDV ALEVPPKREVVVYAPLSKKQEIFYTAIVNRTIANMFGSSEKETIELSPTGRPKRRTRKSINYSKIDDFPNELEKLISQIQPEVDRERAVV EVNIPVESEVNLKLQNIMMLLRKCCNHPYLIEYPIDPVTQEFKIDEELVTNSGKFLILDRMLPELKKRGHKVLLFSQMTSMLDILMDYCH LRDFNFSRLDGSMSYSEREKNMHSFNTDPEVFIFLVSTRAGGLGINLTAADTVIIYDSDWNPQSDLQAQDRCHRIGQTKPVVVYRLVTAN TIDQKIVERAAAKRKLEKLIIHKNHFKGGQSGLNLSKNFLDPKELMELLKSRDYEREIKGSREKVISDKDLELLLDRSDLIDQMNASGPI -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for CYP2C18-HELLS |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for CYP2C18-HELLS |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for CYP2C18-HELLS |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | CYP2C18 | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
Hgene | CYP2C18 | C0206726 | gliosarcoma | 1 | CTD_human |
Hgene | CYP2C18 | C0376358 | Malignant neoplasm of prostate | 1 | CTD_human |
Tgene | HELLS | C4310798 | IMMUNODEFICIENCY-CENTROMERIC INSTABILITY-FACIAL ANOMALIES SYNDROME 4 | 2 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
Tgene | HELLS | C0023893 | Liver Cirrhosis, Experimental | 1 | CTD_human |
Tgene | HELLS | C0032460 | Polycystic Ovary Syndrome | 1 | CTD_human |
Tgene | HELLS | C0152013 | Adenocarcinoma of lung (disorder) | 1 | CTD_human |
Tgene | HELLS | C0398788 | Immunodeficiency syndrome, variable | 1 | GENOMICS_ENGLAND |
Tgene | HELLS | C1136382 | Sclerocystic Ovaries | 1 | CTD_human |